Sun Pharmaceutical Industries
has completed its acquisition and
begun the integration of its new
opiates business in Australia.
Sun Pharma bought the division
from GlaxoSmithKline earlier this
year (PD 04 Mar), including two
opiates manufacturing facilities in
Port Fairy and Latrobe.
The acquisition allows Sun
Pharma to expand its narcotics raw
material market share and enhance
its opiate alkaloids portfolio, as
well as strengthening its strategic
position in global opiates.
Anil Kumar Jain, ceo of API
Business, Sun Pharma, said the
company will be able to capitalise
on its “global ranking in the
specialty generics market.”The above article was sent to subscribers in Pharmacy Daily's issue from 02 Sep 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Sep 15
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.